LUTS: Lower Urinary Tract Symptoms最新文献

{"title":"In Older Men With Persistent Nocturia Due to Nocturnal Polyuria, Desmopressin Is Effective for Those With Higher Muscle Mass.","authors":"Keisuke Ishikawa, Akira Tsujimura, Riho Kasai, Yukiko Ota, Takashi Kanda, Yuta Anno, Haruhiko Wakita, Ayumu Taniguchi, Yuka Uesaka, Taiji Nozaki, Masato Shirai, Shigeo Horie","doi":"10.1111/luts.70063","DOIUrl":"https://doi.org/10.1111/luts.70063","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the efficacy of desmopressin in older men with persistent nocturia due to nocturnal polyuria and then determine the independent factors affecting the efficacy of desmopressin.</p><p><strong>Methods: </strong>Desmopressin 50 mg was administered for 12 weeks to 49 patients (76.3 ± 7.3 years) with persistent nocturia. Physical factors including prostate volume, muscle mass, basal metabolic rate, maximum flow rate, voiding diary, serum sodium, and scores of several questionnaires were evaluated. First, we evaluated the efficacy of desmopressin and then investigated the independent factors influencing its efficacy.</p><p><strong>Results: </strong>Nocturnal urinary frequency decreased significantly from 3.9 ± 1.0 to 1.9 ± 1.1 times/night. The nocturnal urine volume and nocturnal polyuria index significantly decreased from 761.6 ± 273.8 to 445.5 ± 159.3 mL and from 45.5% ± 10.2% to 32.3% ± 14.4% respectively. The total International Prostate Symptom Score improved significantly, as did the Quality of Life index. However, the Overactive Bladder Symptom Score and the Athens Insomnia Scale did not show significant improvement. Only muscle mass at the baseline measurement was identified as a factor predictive of affecting the efficacy of desmopressin based on the decrease in nocturnal urinary frequency.</p><p><strong>Conclusions: </strong>This study is the first, to our knowledge, to determine the independent factors affecting the efficacy of desmopressin.</p>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":"e70063"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rates and Predictors of Persistent LUTS Medication Use After Laser Enucleation of the Prostate.","authors":"Maximilian Filzmayer, Miriam I Traumann, Clara Humke, Matthias J Müller, Philipp C Mandel, Luis A Kluth, Andreas Becker, Felix K-H Chun, Marina Kosiba","doi":"10.1111/luts.70062","DOIUrl":"https://doi.org/10.1111/luts.70062","url":null,"abstract":"<p><strong>Objectives: </strong>To assess rates of medication use for lower urinary tract symptoms (LUTS) over time following laser enucleation of the prostate (LEP) and to identify preoperative predictors of persistent use.</p><p><strong>Methods: </strong>We retrospectively analyzed 864 LEP patients from an institutional tertiary-care database (11/2017-05/2023) with available 24-month follow-up on medication use. Patient-reported use of five drug classes (alpha-blockers, 5-alpha-reductase (AR)-inhibitors, anticholinergics, beta-3-agonists, and phosphodiesterase (PDE)-5-inhibitors) was recorded preoperatively and at one, three, 12, and 24 months after the procedure. Univariable and multivariable logistic regression models were fitted to identify predictors of persistent LUTS medication use.</p><p><strong>Results: </strong>Preoperatively, 84.9% of patients used LUTS medication, decreasing to 12.6% within 24 months of follow-up. Alphablocker (80.9%) and 5-AR-inhibitor (13.8%) use declined to 1.8% and 0%, respectively. Anticholinergic (4.6%) and beta-3-agonist (0.3%) use showed a transient postoperative increase with peaks of 10.9% and 1.0% at 3 months, followed by a decline to 2.7% and 0.4% at 24 months, respectively. PDE-5-inhibitor use (1.8%) increased steadily to 5.4% at 24 months. Patient with persistent use exhibited worse baseline QoL and ICIQ-SF scores and higher rates of adiposity, diabetes mellitus, and ASA score III/IV. In multivariable analysis, only preoperative PDE-5-inhibitor use (adjusted OR 3.26, p = 0.002) and ASA score III/IV (adjusted OR 2.08, p = 0.016) remained independently associated with persistent LUTS medication use.</p><p><strong>Conclusion: </strong>LUTS medication use decreased substantially after LEP, with only a small subset requiring continued medication at 24 months. Preoperative PDE-5-inhibitor use and higher comorbidity burden emerged as independent predictors of persistent LUTS medication use. These findings can refine preoperative counseling regarding postoperative LUTS medication dependence.</p>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":"e70062"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13103631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Frailty and Short-Term Treatment-Related Adverse Events in Patients With Overactive Bladder","authors":"Sohei Iwagami,&nbsp;Hiraku Yamamoto,&nbsp;Haruka Miyai,&nbsp;Masaya Nishihata","doi":"10.1111/luts.70060","DOIUrl":"10.1111/luts.70060","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate whether frailty at treatment initiation is associated with treatment-related adverse events in patients with newly diagnosed overactive bladder (OAB).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective, single-center cohort study included 122 patients who initiated pharmacotherapy for OAB between April 2024 and January 2026. Frailty was evaluated using the Frailty Screening Index and classified as robust, prefrail, or frail. The primary outcome was treatment-related adverse events within 3 months, and independent predictors were identified using multivariable logistic regression. Longitudinal changes in OAB symptoms were examined using linear mixed-effects models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During follow-up, adverse events occurred in 52 patients (42.6%), rising with frailty (4.7%, 40.0%, and 57.3% in robust, prefrail, and frail groups, respectively; <i>p</i> &lt; 0.01 for trend). In multivariable analysis, frailty (odds ratio [OR] 2.97 per status increase, 95% confidence interval [CI] 1.45–6.52; <i>p</i> &lt; 0.01), anticholinergic use (OR 7.96, 95% CI 2.94–24.46; <i>p</i> &lt; 0.01), and baseline post-void residual volume (OR 1.22 per 10 mL increase, 95% CI 1.01–1.34; <i>p</i> = 0.02) were independently associated with adverse events; chronological age was not. Symptom improvement over time did not differ significantly by frailty status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Frailty, rather than chronological age, was associated with short-term treatment-related adverse events among patients starting pharmacotherapy for OAB. Frailty assessment may help identify patients at higher risk of adverse events and support individualized, safety-conscious treatment decisions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Early Postoperative Urinary Incontinence on Presenteeism After Robot-Assisted Radical Prostatectomy for Prostate Cancer: A Prospective Cohort Study","authors":"Noriko Nakayama,&nbsp;Tetsuya Tsuji,&nbsp;Akira Kumagai","doi":"10.1111/luts.70055","DOIUrl":"10.1111/luts.70055","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Urinary incontinence (UI) in the first 3 months after robot-assisted radical prostatectomy (RARP) frequently impairs work performance, yet its quantitative impact on presenteeism remains unclear. This prospective cohort study longitudinally evaluated how early postoperative UI influences presenteeism among employed Japanese men undergoing RARP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We consecutively enrolled 92 employed male patients scheduled for RARP and assessed them preoperatively, at discharge, and at 1- (PS-1) and 3-month (PS-3) post-surgery. Outcomes were the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), WHO Health and Work Performance Questionnaire (HPQ)-Presenteeism Scale, King's Health Questionnaire (KHQ), and Kessler Psychological Distress Scale (K6).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 92 eligible participants, 85 (92.4%) completed the PS-1 and 80 (87.0%) completed the PS-3 assessment. Median ICIQ-SF total scores increased from 0 (IQR 0–2) preoperatively to 9 (6–12) at PS-1, remaining elevated at 7 (4–10) at PS-3 (<i>p</i> &lt; 0.001). Mean HPQ-presenteeism declined from 81.4% ± 13.9% preoperatively to 64.9% ± 18.8% at PS-1, partially recovering to 75.3% ± 16.1% at PS-3 (<i>p</i> &lt; 0.001). At PS-1, UI impact on daily life (<i>ρ</i> = −0.45) and ICIQ-SF total (<i>ρ</i> = −0.43) were moderately associated with lower presenteeism; at PS-3, correlations persisted and extended to multiple KHQ subscales (<i>ρ</i> = −0.41 to −0.53).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Early postoperative UI after RARP produces a clinically meaningful reduction in work productivity, greatest at PS-1 and still evident at PS-3. Targeted continence care and occupational support during this window may mitigate productivity loss and facilitate sustainable return to work.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use-Results Survey in Japan","authors":"Yoshimasa Ogawa,&nbsp;Kiyotoshi Kuramoto,&nbsp;Atsushi Nakano","doi":"10.1111/luts.70052","DOIUrl":"10.1111/luts.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This report presents the final results of a post-marketing surveillance evaluating the safety of desmopressin orally disintegrating tablets (ODT) in Japanese men with nocturia due to nocturnal polyuria (NP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In total, 1113 Japanese men who received desmopressin ODT for the first time to treat nocturia due to NP were enrolled in a central registry. Of the 1087 patients for which case report forms were collected, 38 did not meet the safety eligibility criteria of the survey. Consequently, the remaining 1049 patients were included in the analysis. The participants were followed for up to 52 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean age of the total population was 75.0 ± 9.6 years. A total of 351 adverse drug reactions (ADRs) were reported in 259 patients, including 11 serious ADRs in 7 patients (0.7%). The most common ADR was hyponatremia, which occurred in 140 patients (13.3%). Among the 19 patients (13.6%) presenting hyponatremia related symptoms, no reports of confusion, seizures, stupor, or coma was recorded. Multivariate analysis identified age ≥ 75 years, a history of benign prostatic hyperplasia, and a lower serum sodium level before treatment as risk factors for the development of hypernatremia after the treatment with desmopressin ODT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The survey provides insights into the safety profile of desmopressin ODT in real-clinical practice in Japan. Patients aged ≥ 75 years, those with underlying medical conditions, and those with abnormal clinical laboratory values, such as reduced renal function or a baseline serum sodium level of &lt; 140 mmol/L, should be closely monitored for the development of hyponatremia during desmopressin treatment for nocturia due to NP.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment-Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet-Rich Plasma in Bladder Pain Syndrome","authors":"Wan-Ru Yu,&nbsp;Tsung-Cheng Hsieh,&nbsp;Ya-Hui Wu,&nbsp;Hann-Chorng Kuo","doi":"10.1111/luts.70057","DOIUrl":"10.1111/luts.70057","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To estimate response to intravesical onabotulinumtoxinA (BoNT-A) injection and platelet-rich plasma (PRP) therapy in females with bladder pain syndrome (BPS) without Hunner lesions, we developed and internally validated treatment-specific predictive models integrating clinical characteristics, bladder functional parameters, and urinary biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Females with BPS who underwent intravesical BoNT-A injection or PRP therapy were retrospectively analyzed. A total of 273 female patients were included in the final analysis. Multivariable logistic regression models were constructed to predict treatment response, defined as a Global Response Assessment score ≥ 2. Model discrimination was assessed using the area under the receiver operating characteristic (ROC) curve. For interpretability, nomogram visualizations and a conceptual framework are provided in the Supporting Information.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The BoNT-A model demonstrated acceptable discrimination (area under the ROC curve: 0.789), whereas the PRP model showed superior discriminatory performance (area under the ROC curve: 0.895). Distinct clinical features and biomarker patterns contributed to each treatment-specific model, suggesting differential underlying mechanisms. Internal validation revealed higher observed response rates when the administered therapy matched the model-predicted higher probability of response, supporting internal model concordance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Treatment-specific models combining clinical, urodynamic, and urinary biomarker data provide mechanistic insight into heterogeneous response profiles to BoNT-A and PRP in females with BPS. While these models may inform future phenotype-guided research and prospective validation, external validation is required before broader clinical implementation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α1-Blocker Treatment: A Multi-Center Prospective Randomized Controlled Study (VATON Study)","authors":"Masaki Yoshida,&nbsp;Yoshinori Nishino,&nbsp;Hiroshi Nagae,&nbsp;Shinobu Kato,&nbsp;Sadaaki Sakamoto,&nbsp;Morifumi Hojo,&nbsp;Toshihide Miyauchi,&nbsp;Shinji Kageyama,&nbsp;Shinichi Takahashi,&nbsp;Hideya Kuroda,&nbsp;Naoki Mori,&nbsp;Yasuhiro Kasagi,&nbsp;Koichi Masunaga,&nbsp;Yoshiyuki Nabeshima,&nbsp;Masanori Nomiya,&nbsp;Koichi Iwashita,&nbsp;Koichi Miyamae,&nbsp;Masayuki Otani,&nbsp;Kazuya Kawahara,&nbsp;Makoto Ikeda,&nbsp;Shinichi Kubono,&nbsp;Nobuhiro Haga","doi":"10.1111/luts.70053","DOIUrl":"10.1111/luts.70053","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the efficacy and safety of vibegron add-on therapy for persistent overactive bladder (OAB) symptoms after <i>α</i>₁-blocker monotherapy for benign prostatic hyperplasia (BPH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eligible patients were aged ≥ 50 years and diagnosed with BPH. All patients had received an <i>α</i>₁-blocker for ≥ 8 weeks, yet had persistent OAB symptoms. Patients were randomized 1:1 to receive add-on vibegron (50 mg) or to continue <i>α</i>₁-blocker monotherapy. The primary efficacy endpoint was the between-group difference from baseline (week 0) to week 12 in total overactive bladder symptom score (OABSS). Secondary endpoints included bladder diary parameters, OABSS subscores; International Prostate Symptom Score total, storage/voiding, quality-of-life score; and patient satisfaction assessed by the Patient Global Impression. Safety was assessed by recording treatment-emergent adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 158 patients were randomized into two groups (<i>n</i> = 79 each). The least-squares mean change in the primary endpoint (OABSS total score) was −1.9 (95% confidence interval [CI]: −2.4 to −1.5) with <i>α</i>₁-blocker monotherapy and −3.3 (95% CI: −3.8 to −2.9) with vibegron add-on therapy; the between-group difference was −1.4 (95% CI: −2.0 to −0.8; <i>p</i> &lt; 0.001), indicating a significant improvement with add-on therapy. Across the secondary endpoints, favorable outcomes were observed. Higher satisfaction was reported in the vibegron add-on therapy group than in the <i>α</i>₁-blocker monotherapy group. Vibegron was well tolerated, and no serious drug-related treatment-emergent adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Vibegron add-on therapy to an <i>α</i>₁-blocker may be effective and safe for treating BPH with persistent OAB symptoms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Survey on Real-World Transurethral Surgery Procedures for Bladder Pain Syndrome and Interstitial Cystitis","authors":"Niimi Aya,&nbsp;Akiyama Yoshiyuki,&nbsp;Furuta Akira,&nbsp;Matsuo Tomohiro,&nbsp;Kitta Takeya,&nbsp;Otsuka Atsushi,&nbsp;Mitsui Takahiko,&nbsp;Masumori Naoya,&nbsp;Matsukawa Yoshihisa,&nbsp;Torimoto Kazumasa,&nbsp;Kinjo Manami,&nbsp;Chiba Hiroki,&nbsp;Nomiya Akira,&nbsp;Maeda Daichi,&nbsp;Homma Yukio","doi":"10.1111/luts.70058","DOIUrl":"10.1111/luts.70058","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate real-world practices in transurethral surgeries for bladder pain syndrome (BPS) and interstitial cystitis (IC) in Japan, with a focus on procedural characteristics of hydrodistension (HD) and transurethral elimination of Hunner lesions (TUEH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An internet-based questionnaire was sent to all members of the Society of Interstitial Cystitis of Japan in November 2024. The survey inquired about institutional characteristics, the number of procedures performed in the previous 12 months, and detailed surgical techniques. BPS was defined by the absence of Hunner lesions, and IC by their presence. Responses were analyzed to describe procedural patterns and compare practices between HD and TUEH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 205 eligible members, 86 responded (response rate: 42%). Among them, 52 had performed HD for BPS and 67 had performed TUEH for IC within the study period. Most surgeons distended the bladder to a preset pressure of ≤ 80 cm H₂O for 3–10 min and repeated the procedure at least twice during HD. At TUEH, coagulation was preferred over resection to eliminate Hunner lesions. HD was frequently co-performed, though the sequence of elimination and HD varied. Compared to HD, TUEH more often relied on abdominal palpation rather than fixed pressure, used shorter distension time, and involved longer catheter placement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This nationwide survey highlights contemporary surgical practices for BPS and IC in Japan. These findings may help clinicians evaluate and refine their own approaches to transurethral interventions for these complex conditions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147434211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overactive Bladder Symptoms as a Predictor of Longitudinal Decline in Grip Strength in Community-Dwelling Men: A 4-Year Longitudinal Study","authors":"Hiroyuki Sato,&nbsp;Teppei Okamoto,&nbsp;Tomoko Hamaya,&nbsp;Hirotake Kodama,&nbsp;Takuma Narita,&nbsp;Jotaro Mikami,&nbsp;Naoki Fujita,&nbsp;Hayato Yamamoto,&nbsp;Atsushi Imai,&nbsp;Koichi Murashita,&nbsp;Shigeyuki Nakaji,&nbsp;Shingo Hatakeyama","doi":"10.1111/luts.70056","DOIUrl":"10.1111/luts.70056","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Lower urinary tract symptoms (LUTS) are associated with sarcopenia in men. However, it is not clear whether LUTS are related to the decline in physical function. We investigated the longitudinal association between the LUTS severity and the grip strength change in community-dwelling men.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A 4-year longitudinal study was conducted using data from 151 men (median age 53 years) enrolled in the Iwaki Health Promotion Project. Grip strength change was calculated as the difference between 2015 and 2019 measurements. LUTS severity was assessed with the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). Baseline variables included age, Aging Male Symptoms score, serum testosterone, albumin, interleukin-6, HbA1c, daily exercise, skeletal muscle mass index, and percent body fat. Correlations and multiple regression analyses were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median age and baseline grip strength were 53 years and 41.3 kg, respectively. Grip strength decreased significantly after 4 years, with a median value of −1.1 kg. There was a significant negative correlation between total OABSS, OABSS Q3 (frequency of urinary urgency, <i>r</i> = −0.234, <i>p</i> = 0.003), Q4 (frequency of urge urinary incontinence, <i>r</i> = −0.190, <i>p</i> = 0.020), and grip strength change, whereas the IPSS voiding symptoms domain was not. Multiple regression analysis showed that only the total score of OABSS Q3 and Q4 was significantly correlated with grip strength change (standardized <i>β</i> = −0.930, <i>p</i> = 0.012).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The main symptoms of OAB may be indicators of the grip strength decline in men.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12968119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Failed Trial Without Catheter Post Rezūm in Non-Catheter Dependent Patients: Risk Factors From the Canadian Rezūm Registry","authors":"Omar Buksh,&nbsp;Roseanne Ferreira,&nbsp;Mario Henrique Bitar Siqueira,&nbsp;Naeem Bhojani,&nbsp;Bilal Chughtai,&nbsp;Kevin C. Zorn,&nbsp;Dean S. Elterman","doi":"10.1111/luts.70054","DOIUrl":"10.1111/luts.70054","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Rezūm has become an increasingly popular surgical approach for treating bladder outlet obstruction. Despite the practice of routinely placing a Foley catheter, successful TWOC (Trial Without Catheter) remains variable. This study seeks to identify the TWOC failure incidence and risk factors to inform clinical decisions and enhance patient counseling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective review of non-catheter dependent patients who underwent Rezūm therapy between April 2019 and June 2023 in two high-volume Canadian centers. All patients received a urinary catheter post-treatment. International Prostate Symptom Score (IPSS), QoL, Qmax, and PVR were evaluated. Risk factors for TWOC failure were determined through logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 406 patients, 99 patients (24.4%) failed TWOC on the first attempt. Median time to TWOC was 7 days (range 3–30 days). Successful and failure groups had no significant difference in terms of average catheterization time, baseline prostate volume, PVR, or total number of injections per prostate volume ratio. A higher rate of UTIs was observed in the TWOC failure group (10.6% vs. 2.6%, <i>p</i> = 0.003). During the 12-month follow-up period, 12 patients developed episodes of urinary retention following Rezūm therapy. Baseline PVR was not a risk factor for failed TWOC in our cohort (<i>p</i> = 0.95). Higher IPSS was a predictor for TWOC failure (OR 1.04 95% CI: 1.01–1.08).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>About one in four patients failed the first TWOC after Rezūm therapy. High baseline IPSS was identified as the only risk factor for TWOC failure in our cohort. Despite this, overall urinary symptoms improved in all patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147369594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}